Correction to: miR-124-3p regulates cell proliferation, invasion, apoptosis and bioenergetics by targeting PIM1 in astrocytoma, (Cancer Sci, (2016), 107, (899-907), 10.1111/cas.12946);MicroRNA-124-3p regulates cell proliferation, invasion, apoptosis, and bioenergetics by targeting PIM1 in astrocytoma

Cancer Science

Volumn 107, Issue 7, 2016, Pages 899-907

  Deng, Danni ^a   Wang, Lei ^b   Chen, Yao ^c   Li, Bowen ^a   Xue, Lian ^a   Shao, Naiyuan ^a   Wang, Qiang ^a   Xia, Xiwei ^a   Yang, Yilin ^a   Zhi, Feng ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b XUZHOU CENTRAL HOSPITAL   (China)

^c Changzhou Center for Biotech Development   (China)

Author keywords

Apoptosis; bioenergetics; invasion; miR 124 3p; PIM1

Indexed keywords

MESSENGER RNA; MICRORNA 124; MICRORNA 124 3P; PROTEIN KINASE PIM 1; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; AGED; APOPTOSIS; ARTICLE; ASTROCYTOMA; ASTROCYTOMA CELL LINE; BIOENERGY; CANCER GRADING; CANCER INHIBITION; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; EPIGENETIC REPRESSION; FEMALE; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

EID: 84978795461     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.15534     Document Type: Erratum

References (54)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492–507.
2. Rousseau A, Mokhtari K, Duyckaerts C. The 2007 WHO classification of tumors of the central nervous system – what has changed? Curr Opin Neurol 2008; 21: 720–7.
3. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60: 166–93.
4. Gabayan AJ, Green SB, Sanan A et al. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery 2006; 58: 701–9; discussion -9.
5. Luo JW, Wang X, Yang Y, Mao Q. Role of micro-RNA (miRNA) in pathogenesis of glioblastoma. Eur Rev Med Pharmacol Sci 2015; 19: 1630–9.
6. Xu J, Zhang T, Wang T, You L, Zhao Y. PIM kinases: an overview in tumors and recent advances in pancreatic cancer. Future Oncol 2014; 10: 865–76.
7. Narlik-Grassow M, Blanco-Aparicio C, Carnero A. The PIM family of serine/threonine kinases in cancer. Med Res Rev 2014; 34: 136–59.
8. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12: 861–74.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–97.
10. Dvinge H, Git A, Graf S et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 2013; 497: 378–82.
11. Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259–69.
12. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010; 10: 389–402.
13. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834–8.
14. Zhi F, Zhou G, Shao N et al. miR-106a-5p inhibits the proliferation and migration of astrocytoma cells and promotes apoptosis by targeting FASTK. PLoS ONE 2013; 8: e72390.
15. Zhi F, Wang Q, Deng D et al. MiR-181b-5p downregulates NOVA1 to suppress proliferation, migration and invasion and promote apoptosis in astrocytoma. PLoS ONE 2014; 9: e109124.
16. Zhi F, Gong G, Xu Y et al. Activated beta-catenin forces N2A cell-derived neurons back to tumor-like neuroblasts and positively correlates with a risk for human neuroblastoma. Int J Biol Sci 2012; 8: 289–97.
17. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115: 787–98.
18. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol 2004; 2: e363.
19. Zhi F, Chen X, Wang S et al. The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer 2010; 46: 1640–9.
20. Leung CO, Wong CC, Fan DN et al. PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma. Oncotarget 2015; 6: 10880–92.
21. Cen B, Xiong Y, Song JH et al. The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling. Mol Cell Biol 2014; 34: 2517–32.
22. Padmanabhan A, Gosc EB, Bieberich CJ. Stabilization of the prostate-specific tumor suppressor NKX3.1 by the oncogenic protein kinase Pim-1 in prostate cancer cells. J Cell Biochem 2013; 114: 1050–7.
23. Jie W, He QY, Luo BT et al. Inhibition of Pim-1 attenuates the proliferation and migration in nasopharyngeal carcinoma cells. Asian Pac J Trop Med 2012; 5: 645–50.
24. Brault L, Menter T, Obermann EC et al. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma. Br J Cancer 2012; 107: 491–500.
25. Kim W, Youn H, Kwon T et al. PIM1 kinase inhibitors induce radiosensitization in non-small cell lung cancer cells. Pharmacol Res 2013; 70: 90–101.
26. Malinen M, Jaaskelainen T, Pelkonen M et al. Proto-oncogene PIM-1 is a novel estrogen receptor target associating with high grade breast tumors. Mol Cell Endocrinol 2013; 365: 270–6.
27. Zhang G, Liu Z, Cui G, Wang X, Yang Z. MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells. Tumour Biol 2014; 35: 11137–45.
28. Thomas M, Lange-Grunweller K, Weirauch U et al. The proto-oncogene Pim-1 is a target of miR-33a. Oncogene 2012; 31: 918–28.
29. Lee MR, Kim JS, Kim KS. miR-124a is important for migratory cell fate transition during gastrulation of human embryonic stem cells. Stem Cells 2010; 28: 1550–9.
30. Cheng LC, Pastrana E, Tavazoie M, Doetsch F. miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nat Neurosci 2009; 12: 399–408.
31. Sun Y, Luo ZM, Guo XM, Su DF, Liu X. An updated role of microRNA-124 in central nervous system disorders: a review. Front Cell Neurosci 2015; 9: 193.
32. Lu SH, Jiang XJ, Xiao GL, Liu DY, Yuan XR. miR-124a restoration inhibits glioma cell proliferation and invasion by suppressing IQGAP1 and beta-catenin. Oncol Rep 2014; 32: 2104–10.
33. Lv Z, Yang L. MiR-124 inhibits the growth of glioblastoma through the downregulation of SOS1. Mol Med Rep 2013; 8: 345–9.
34. Zhao WH, Wu SQ, Zhang YD. Downregulation of miR-124 promotes the growth and invasiveness of glioblastoma cells involving upregulation of PPP1R13L. Int J Mol Med 2013; 32: 101–7.
35. Xie YK, Huo SF, Zhang G et al. CDA-2 induces cell differentiation through suppressing Twist/SLUG signaling via miR-124 in glioma. J Neurooncol 2012; 110: 179–86.
36. An L, Liu Y, Wu A, Guan Y. microRNA-124 inhibits migration and invasion by down-regulating ROCK1 in glioma. PLoS ONE 2013; 8: e69478.
37. Cai JJ, Qi ZX, Chen LC, Yao Y, Gong Y, Mao Y. miR-124 suppresses the migration and invasion of glioma cells in vitro via Capn4. Oncol Rep 2016; 35: 284–90.
38. Silber J, Lim DA, Petritsch C et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 2008; 6: 14.
39. Xia H, Cheung WK, Ng SS et al. Loss of brain-enriched miR-124 microRNA enhances stem-like traits and invasiveness of glioma cells. J Biol Chem 2012; 287: 9962–71.
40. Shi Z, Chen Q, Li C et al. MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. Neuro Oncol 2014; 16: 1341–53.
41. Mucaj V, Lee SS, Skuli N et al. MicroRNA-124 expression counteracts pro-survival stress responses in glioblastoma. Oncogene 2015; 34: 2204–14.
42. Suzhi Z, Liang T, Yuexia P et al. Gap junctions enhance the antiproliferative effect of microRNA-124-3p in glioblastoma cells. J Cell Physiol 2015; 230: 2476–88.
43. Chen T, Wang XY, Li C, Xu SJ. Downregulation of microRNA-124 predicts poor prognosis in glioma patients. Neurol Sci 2015; 36: 131–5.
44. Eguia-Aguilar P, Perezpena-Diazconti M, Benadon-Darszon E et al. Reductions in the expression of miR-124-3p, miR-128-1, and miR-221-3p in pediatric astrocytomas are related to high-grade supratentorial, and recurrent tumors in Mexican children. Childs Nerv Syst 2014; 30: 1173–81.
45. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21: 297–308.
46. Wang B, Sun F, Dong N et al. MicroRNA-7 directly targets insulin-like growth factor 1 receptor to inhibit cellular growth and glucose metabolism in gliomas. Diagn Pathol 2014; 9: 211.
47. Dai DW, Lu Q, Wang LX et al. Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM. BMC Cancer 2013; 13: 478.
48. Zhao S, Liu H, Liu Y et al. miR-143 inhibits glycolysis and depletes stemness of glioblastoma stem-like cells. Cancer Lett 2013; 333: 253–60.
49. Godlewski J, Nowicki MO, Bronisz A et al. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell 2010; 37: 620–32.
50. Nie S, Li K, Huang Y, Hu Q, Gao X, Jie S. miR-495 mediates metabolic shift in glioma cells via targeting Glut1. J Craniofac Surg 2015; 26: e155–8.
51. Zhang F, Beharry ZM, Harris TE et al. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther 2009; 8: 846–53.
52. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003; 4: 147–58.
53. Wang X, Wu Q, Xu B et al. miR-124 exerts tumor suppressive functions on the cell proliferation, motility and angiogenesis of bladder cancer by fine-tuning UHRF1. FEBS J 2015; 282: 4376–88.
54. Chen M, Yi B, Zhu N et al. Pim1 kinase promotes angiogenesis through phosphorylation of endothelial nitric oxide synthase at Ser-633. Cardiovasc Res 2016; 109: 141–50.